News
Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...
Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
The collaboration with Kymera highlights Gilead’s focus on innovative cancer therapies, while the FDA’s approval of Yeztugo underscores its leadership in HIV prevention.
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
10d
Asianet Newsable on MSNGilead’s Yeztugo HIV Shot Poised For Wider Reach After SCOTUS Ruling On Preventive Coverage: Wells FargoThe Supreme Court upheld the Affordable Care Act’s no-cost insurance mandate for preventive care, including HIV PrEP, a move ...
Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health insurers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results